Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of TAK-816 vs ActHIB in healthy infants
jRCT2080221477Phase 3
- Sponsor
- Takeda
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VaxemHIB in Haemophilus influenzae type b disease (Hib), diphtheria, pertussis and 1 more (2 arms), sponsored by Takeda. Primary endpoint: Primary efficacy and safety endpoints.
02
Drugs
VaxemHIB
03
Conditions
Haemophilus influenzae type b disease (Hib)diphtheriapertussisTetanus
Beyond the preview
Go deeper on jRCT2080221477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221477.